Drugmaker Granules India reported consolidated net revenue elevated nearly 8% for the March quarter to ₹119.60 crore from the year-earlier interval.
The net revenue got here on a 16% improve in whole revenue to ₹1,198.87 crore (₹1,033.93 crore) primarily pushed by higher gross sales in key geographies, together with the U.S. and Europe. Revenue share from the U.S. rose to 54% from 48% in the corresponding interval of earlier fiscal.
For 2022-23, net revenue rose 25% to ₹516.59 (₹412.76 crore), whereas whole revenue elevated 20% to ₹4,525.69 crore (₹3,782.52 crore). The revenue development is regardless of the “price erosion challenges in our key geographies, including the U.S.,” CMD Krishna Prasad Chigurupati stated. The firm stated higher rates of interest impacted the development in PAT margin.
The firm declared a remaining dividend of ₹1.50 per share (face worth of ₹1 every) for the fiscal. On Tuesday, Granules shares declined 1.66% to shut at ₹288 on the BSE.
